查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494760

表皮生长因子受体 (EGFR) 抑制剂到 2030 年的全球市场预测：按类型、药物类型、给药方法、分销管道、应用、最终用户和地区进行分析

Epidermal Growth Factor Receptor Inhibitors Market Forecasts to 2030 - Global Analysis By Type, Drug Type, Mode of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2024年全球表皮生长因子受体（EGFR）抑制剂市场规模将达141亿美元，预测期内复合年增长率为14.2%，预计2030年将达314亿美元。

表皮生长因子受体 (EGFR) 抑制剂是一种针对錶皮生长因子受体（一种存在于细胞表面的蛋白质）的药物。 EGFR 参与细胞生长和分裂，其过度活性与某些癌症，特别是肺癌和大肠癌的发生和进展有关。 GFR 抑制剂可单独使用或与化疗或放射线治疗等其他癌症治疗方法合併用于治疗多种癌症。

据美国国立卫生研究院称，近年来，美国各类主要癌症的新病例显着增加，包括肺癌、大肠直肠癌和乳腺癌。 2020年，美国预计将有180万人被诊断出罹患癌症，606,520人将死于该疾病。

扩大标靶治疗的采用

市场正在经历标靶治疗的快速采用，反映了不断变化的治疗模式。标靶治疗透过特异性针对癌细胞并最大限度地减少对健康组织的损害来提高抗癌的精确度。这种模式转移是由研究和开发的进步以及对促进癌症进展的分子途径的深入了解所推动的。随着个人化治疗方法普及普遍，随着对个别患者的个人化治疗的转变，市场有望实现显着成长。

替代治疗的可用性

市场面临着适应替代疗法的挑战。儘管 EGFR 抑制剂有效，但免疫疗法和标靶治疗等替代疗法正在相互竞争。此外，EGFR 抑制剂的抗药性和副作用也增加了复杂性。确保替代疗法的可用性、可负担性和患者意识仍然是重要的障碍。市场必须适应，将这些治疗方法整合到治疗方案中，并满足患者的特定需求以获得最佳结果。

癌症发生率上升

市场上有一个令人担忧的趋势：癌症发生率上升。儘管Erlotinib和Gefitinib等 EGFR 抑制剂的治疗取得了进展，但依赖这些疗法的癌症病例的发生率仍在增加。这可能表明 EGFR 诱发的癌症盛行率增加，或者先前对这些药物有反应的患者可能出现抗药性。这些趋势凸显了继续研究癌症生物学和开发创新治疗策略的必要性。

昂贵的治疗费用

该市场面临着治疗成本高昂的挑战，为患者的取得造成了障碍。儘管它们在治疗某些癌症方面有效，但抑制剂的经济负担限制了它们的普及。这个成本因素凸显了相关人员需要共同努力开发更便宜的选择并探索津贴途径，以确保公平地获得挽救生命的治疗。

COVID-19 的影响：

COVID-19 的爆发对市场产生了重大影响，扰乱了製造、供应链和临床试验。关闭和限制阻碍了患者进入医疗机构，影响了诊断和治疗的开始。然而，随着远端医疗和远端监控的引入，保持了一定的连续性。市场出现了需求波动，并转向优先考虑基本治疗。儘管面临挑战，但持续的研究和开发旨在在大流行的挑战中满足新的需求并优化治疗结果。

预计联合治疗领域在预测期内将是最大的。

预计联合治疗领域在预测期内将是最大的。透过同时针对多个途径，这些疗法旨在提高疗效并克服抗药性机制。 EGFR 抑制剂与化疗、免疫疗法和其他标靶药物的联合治疗正在进行研究，并在多种癌症类型中显示出前景。这些方法为个人化治疗方法提供了新途径，并可透过解决异质性肿瘤特征和适应性抗药性机制来改善患者预后。

在预测期内，大肠直肠癌领域的复合年增长率最高。

由于标靶治疗的进步，预计结直肠癌领域在预测期内将出现最高的复合年增长率。这些抑制剂，如Cetuximab和Panitumumab，透过抑制 EGFR 讯号途径，在改善患者预后方面显示出有希望的结果。由于全球大肠直肠癌盛行率不断上升以及对个人化治疗的需求不断增加，预计 EGFR 抑制剂市场将显着成长。

比最大的地区

由于癌症发病率增加和标靶治疗的进步等因素，预计北美在预测期内将占据最大的市场占有率。这些抑制剂专注于精准医疗，在肺癌和大肠癌等多种癌症的治疗中发挥重要作用。该地区的主要公司继续投资于研发，旨在推出创新治疗方法。

复合年增长率最高的地区：

预计亚太地区在预测期内将维持最高的复合年增长率。该地区经常使用 EGFR 抑制剂治疗的癌症（例如肺癌和大肠癌）的发生率正在增加。人们对癌症的认识不断提高，筛检计画得到加强，从而能够及早发现癌症，从而使更多的患者有资格接受标靶治疗。此外，不断上升的医疗保健成本和意识进一步推动市场成长，创造了以持续的临床试验和产品发布为特征的竞争格局。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球表皮生长因子受体（EGFR）市场：依类型

  • 单株抗体 (mAb)
  • 蛋白酪氨酸激酶抑制剂 (TKI)
  • 联合治疗
  • 其他类型

第六章全球表皮生长因子受体（EGFR）市场：依药物类型

  • Erlotinib
  • Cetuximab
  • Gefitinib
  • Osimertinib
  • Afatinib
  • 其他药物类型

第七章全球表皮生长因子受体（EGFR）市场：依管理模式

  • 口服
  • 静脉

第八章全球表皮生长因子受体（EGFR）市场：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房

第九章全球表皮生长因子受体（EGFR）市场：依应用分类

  • 非小细胞肺癌（NSCLC）
  • 胰臟癌
  • 大肠直肠癌
  • 头颈癌
  • 其他用途

第 10 章全球表皮生长因子受体 (EGFR) 市场：依最终用户分类

  • 医院
  • 癌症治疗中心
  • 学术研究所
  • 其他最终用户

第十一章全球表皮生长因子受体（EGFR）市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Merck & Co.
  • Amgen Inc
  • Eli Lilly and Company
  • OSI Pharmaceuticals Inc
  • Johnson & Johnson
  • Genentech, Inc
  • Pfizer
  • AstraZeneca PLC
  • Bayer AG
  • AbbVie
  • Bristol Myers Squibb
  • Teva Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim
  • Regeneron Pharmaceuticals
Product Code: SMRC26275

According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $14.1 billion in 2024 and is expected to reach $31.4 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of medications that target the epidermal growth factor receptor, a protein found on the surface of cells. EGFR is involved in cell growth and division, and its overactivity is associated with the development and progression of certain types of cancer, particularly lung cancer and colorectal cancer. GFR inhibitors are used in the treatment of various cancers, either alone or in combination with other cancer therapies, such as chemotherapy or radiation therapy.

According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease.

Market Dynamics:

Driver:

Growing adoption of targeted therapies

The market is witnessing a surge in adoption of targeted therapies, reflecting an evolving treatment landscape. Targeted therapies offer precision in combating cancer by specifically targeting cancer cells, minimizing damage to healthy tissue. This paradigm shift is driven by advancements in research and development, alongside increasing understanding of molecular pathways driving cancer progression. With personalized treatment approaches gaining traction, the market is poised for substantial growth as it moves towards tailored therapies for individual patients.

Restraint:

Availability of alternative therapies

The market faces challenges in accommodating alternative therapies. Despite the effectiveness of EGFR inhibitors, alternative treatments like immunotherapy and targeted therapies pose competition. Additionally, resistance to EGFR inhibitors and adverse effects contribute to the complexity. Ensuring accessibility, affordability, and patient awareness of alternative therapies remain key hurdles. The market must adapt by integrating these therapies into treatment protocols and addressing patient-specific needs for optimal outcomes.

Opportunity:

Rising cancer rates

The market has seen a concerning trend of rising cancer rates. Despite advancements in treatment utilizing EGFR inhibitors, such as Erlotinib and Gefitinib, the incidence of cancer cases reliant on these therapies has increased. This may indicate either a growing prevalence of EGFR-driven cancers or potential resistance development in patients previously responsive to these drugs. Such trends underscore the need for continued research into cancer biology and the development of innovative therapeutic strategies.

Threat:

High cost of treatment

The market faces challenges due to high treatment costs, posing a barrier to accessibility for patients. Despite their efficacy in treating certain cancers, the financial burden associated with these inhibitors limits their widespread adoption. This cost factor underscores the need for collaborative efforts among stakeholders to develop more affordable options or explore avenues for subsidization to ensure equitable access to life-saving treatments.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Market, causing disruptions in manufacturing, supply chains, and clinical trials. Lockdowns and restrictions hindered patient access to healthcare facilities, affecting diagnosis and treatment initiation. However, with the adoption of telemedicine and remote monitoring, some continuity was maintained. The market witnessed fluctuations in demand, with a shift towards prioritizing essential treatments. Despite challenges, ongoing research and development efforts persisted, aiming to address emerging needs and optimize therapeutic outcomes amidst the pandemic's challenges.

The combination therapies segment is expected to be the largest during the forecast period

The combination therapies segment is expected to be the largest during the forecast period. By targeting multiple pathways simultaneously, these therapies aim to enhance efficacy and overcome resistance mechanisms. Combinations of EGFR inhibitors with chemotherapy, immunotherapy, and other targeted agents are being explored, showing potential in various cancer types. Such approaches offer new avenues for personalized treatment regimens and may improve patient outcomes by addressing heterogeneous tumor profiles and adaptive resistance mechanisms.

The colorectal cancer segment is expected to have the highest CAGR during the forecast period

The colorectal cancer segment is expected to have the highest CAGR during the forecast period driven by advancements in targeted therapies. These inhibitors, such as cetuximab and panitumumab, have shown promising results in improving patient outcomes by inhibiting EGFR signaling pathways. With increasing prevalence of colorectal cancer globally, coupled with growing demand for personalized treatment approaches, the EGFR inhibitors market is poised for significant growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by factors such as increasing cancer prevalence and advancements in targeted therapies. With a focus on precision medicine, these inhibitors play a crucial role in treating various cancers, including lung and colorectal cancer. Key players in the region continue to invest in research and development, aiming to introduce innovative therapies.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region has witnessed a rise in the incidence of cancer, including lung cancer and colorectal cancer, which are often treated with EGFR inhibitors. Increasing awareness about cancer and the availability of screening programs have led to earlier detection of cancers, resulting in more patients being eligible for targeted therapies. Moreover, rising healthcare expenditure and awareness further bolster market growth, fostering a competitive landscape characterized by ongoing clinical trials and product launches.

Key players in the market

Some of the key players in Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc, Eli Lilly and Company, OSI Pharmaceuticals Inc, Johnson & Johnson, Genentech, Inc, Pfizer, AstraZeneca PLC, Bayer AG, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim and Regeneron Pharmaceuticals.

Key Developments:

In May 2023, Eli Lilly and Innovent Biologics, Inc. jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT(R) (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).

In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.

Types Covered:

  • Monoclonal Antibodies (mAbs)
  • Tyrosine Kinase Inhibitors (TKIs)
  • Combination Therapies
  • Other Types

Drug Types Covered:

  • Erlotinib
  • Cetuximab
  • Gefitinib
  • Osimertinib
  • Afatinib
  • Other Drug Types

Mode of Administration Covered:

  • Oral
  • Intravenous

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Non-Small Cell Lung Cancer (NSCLC)
  • Pancreatic Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Other Applications

End Users Covered:

  • Hospitals
  • Cancer Treatment Centers
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epidermal Growth Factor Receptor (EGFR) Market, By Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies (mAbs)
  • 5.3 Tyrosine Kinase Inhibitors (TKIs)
  • 5.4 Combination Therapies
  • 5.5 Other Types

6 Global Epidermal Growth Factor Receptor (EGFR) Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Erlotinib
  • 6.3 Cetuximab
  • 6.4 Gefitinib
  • 6.5 Osimertinib
  • 6.6 Afatinib
  • 6.7 Other Drug Types

7 Global Epidermal Growth Factor Receptor (EGFR) Market, By Mode of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous

8 Global Epidermal Growth Factor Receptor (EGFR) Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Epidermal Growth Factor Receptor (EGFR) Market, By Application

  • 9.1 Introduction
  • 9.2 Non-Small Cell Lung Cancer (NSCLC)
  • 9.3 Pancreatic Cancer
  • 9.4 Colorectal Cancer
  • 9.5 Head and Neck Cancer
  • 9.6 Other Applications

10 Global Epidermal Growth Factor Receptor (EGFR) Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Cancer Treatment Centers
  • 10.4 Academic & Research Institutes
  • 10.5 Other End Users

11 Global Epidermal Growth Factor Receptor (EGFR) Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novartis AG
  • 13.2 F. Hoffmann-La Roche Ltd
  • 13.3 Merck & Co.
  • 13.4 Amgen Inc
  • 13.5 Eli Lilly and Company
  • 13.6 OSI Pharmaceuticals Inc
  • 13.7 Johnson & Johnson
  • 13.8 Genentech, Inc
  • 13.9 Pfizer
  • 13.10 AstraZeneca PLC
  • 13.11 Bayer AG
  • 13.12 AbbVie
  • 13.13 Bristol Myers Squibb
  • 13.14 Teva Pharmaceutical Industries
  • 13.15 Takeda Pharmaceutical Company Limited
  • 13.16 Boehringer Ingelheim
  • 13.17 Regeneron Pharmaceuticals

List of Tables

  • Table 1 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Monoclonal Antibodies (mAbs) (2021-2030) ($MN)
  • Table 4 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Tyrosine Kinase Inhibitors (TKIs) (2021-2030) ($MN)
  • Table 5 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Combination Therapies (2021-2030) ($MN)
  • Table 6 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 8 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Erlotinib (2021-2030) ($MN)
  • Table 9 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Cetuximab (2021-2030) ($MN)
  • Table 10 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Gefitinib (2021-2030) ($MN)
  • Table 11 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Osimertinib (2021-2030) ($MN)
  • Table 12 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Afatinib (2021-2030) ($MN)
  • Table 13 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 14 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Mode of Administration (2021-2030) ($MN)
  • Table 15 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 17 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 18 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 19 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 21 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Non-Small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 23 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
  • Table 24 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 25 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Head and Neck Cancer (2021-2030) ($MN)
  • Table 26 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 30 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
  • Table 31 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.